Stock Market Update - October 28, 2025
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. VSEE - VSee Health, Inc.
Price: $1.06 | Change: +71.66% ($0.4425)
VSEE just saw a notable 71.66% gain, primarily driven by a significant announcement. VSee Health, Inc. recently secured a coveted FedRAMP High Authorization from the U.S. Department of Health and Human Services (HHS). This authorization means their telehealth platform meets the federal government's most stringent security standards for sensitive data, paving the way for wider adoption by other federal agencies.
This clearance is a huge catalyst, allowing VSee to easily partner with government entities and streamlining how agencies can integrate their high-security healthcare technology. The news triggered a dramatic market response, with shares reportedly surging up to 285% during the trading session on the day of the announcement. This positive momentum was also supported by other good news, including eliminating over $5 million in debt and securing a multi-year teleradiology contract worth over $10 million.
What makes this especially interesting is the sheer importance of the FedRAMP High authorization for a company like VSee. It not only validates their commitment to top-tier security but also unlocks a massive new market opportunity within the federal sector, setting the stage for potential long-term growth.
2. XHLD - TEN Holdings, Inc. Common Stock
Price: $0.425 | Change: +51.89% ($0.1452)
XHLD recently saw a notable 51.89% surge, primarily driven by a strategic partnership and the exciting prospects of its upcoming "Ten Events Pro" platform. TEN Holdings announced an agreement with V-Cube Inc., positioning itself to deliver advanced enterprise communication technology within the estimated $34.4 billion North American virtual events market.
Adding to the positive momentum, their "Ten Events Pro" platform, set for a Q1 2026 launch, aims to disrupt the global corporate events market with its AI-driven analytics and CRM integration. An analyst from Litchfield Hills initiated coverage with a "Strong Buy" rating and an $8.00 price target earlier in the year, signaling significant upside. The company also secured a $20 million equity line and executed a $1 million share buyback, actions that often reinforce investor confidence.
3. MCTA - Charming Medical Limited Class A Ordinary Shares
Price: $14.21 | Change: +46.95% ($4.54)
MCTA:NASDAQ recently soared with an impressive 46.95% gain following its Initial Public Offering (IPO) on October 21, 2025. The Hong Kong-based company, Charming Medical Limited, initially priced its Class A shares at $4.00. A significant catalyst for the surge occurred when the underwriters fully exercised their over-allotment option on October 28, purchasing an additional 240,000 shares. This move clearly signals robust investor demand and strong market confidence right out of the gate.
Charming Medical specializes in Traditional Chinese Medicine (TCM)-inspired therapies and products, offering a unique niche in the market. The successful capital raise, bolstered by the over-allotment, brought in approximately US$7.36 million in gross proceeds. The company plans to utilize these funds for expanding its business, pursuing strategic investments, funding research and development, and for general corporate purposes. This combination of a unique offering, successful fundraising, and a clear growth strategy has fueled positive market sentiment and driven the stock's impressive performance post-IPO.
4. CARM - Carisma Therapeutics, Inc.
Price: $0.059 | Change: +46.77% ($0.0188)
CARM posted a remarkable 46.77% gain around late October 2025, which might seem like great news. However, digging a little deeper reveals a more complex story for Carisma Therapeutics. This surge occurred despite a wave of challenging news for the company, including a Nasdaq delisting notice, executive terminations, and an announced wind-down of operations, all following earlier plans to pause R&D and explore strategic alternatives.
So, what fueled the rally? This counter-intuitive price movement was likely due to the extreme volatility often seen in low-priced stocks facing severe distress. While a few technical analyses noted minor "buy signals," these were overwhelmingly overshadowed by negative forecasts and company-specific news painting a picture of a business in significant trouble, not one on the rebound.
This situation highlights that not all stock gains are driven by positive fundamental developments. Sometimes, what looks like a strong surge can simply be the result of market dynamics in a highly unstable stock, reminding us to always look beyond the headline percentage.
5. CTHR - Charles & Colvard, Ltd.
Price: $0.7 | Change: +39.97% ($0.1999)
CTHR recently saw a dazzling 39.97% gain! Charles & Colvard, a key player in the lab-grown diamond market, sparkled after announcing a strategic partnership with Ethara Capital. This collaboration is set to significantly expand CTHR's offerings of lab-grown diamonds for both direct-to-consumer and wholesale buyers.
The excitement stems from Ethara Capital bringing substantial operational capacity to the table. Their affiliates control over 3,000 diamond-growing machines, providing the crucial infrastructure for CTHR to broaden its Caydia® lab-grown diamond jewelry lines and introduce them to fresh markets. This partnership builds on a previous financial arrangement, with Ethara recently converting part of an earlier note into common equity, signaling a deeper commitment.
This strategic expansion into the burgeoning lab-grown diamond market, supported by a powerful partner with extensive manufacturing capabilities, is a clear catalyst for the positive movement in CTHR's stock.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.